AGM attendance

The Starpharma AGM revealed a few things:

1. Priostar Glyphosate, while chemically more effective than standard Glyphosate would not be significantly more expensive because of the very small quantities of dendrimer required. This is important for commercialisation and had not previously been made clear, at least to me.

2. The subject of Alchemia was raised by Jackie and she emphasised the different approach between the two companies, with ACL pursuing its own expensive Phase lll trials as opposed to the Starpharma approach which conducts only the initial research then licences its IP to big pharma to conduct the later phases of trials.

3. The results of the BV symptomatic relief trial were in and due to be released shortly. While this will not deliver US accreditation it will allow Vivagel to proceed in other markets and with the prevalence of the Internet and social networking a market would be likely to become established.

4. The oncology trials were all going well and while they are still increasing the doses on the docotexal trials to maximum tolerable levels, they are already seeing improved results.

5. Short selling and market manipulation were raised both by Jackie and shareholders. Not much the company could do about it.

All in all I felt my money was in good hands and while the SP is disappointing the prospects were good. The AGM packs included a number of recent broker valuations with targets in the range $1.10 to $1.50.